LMR Partners’s Fennec Pharmaceuticals FENC Stock Holding History

LMR Partners’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,402	Closed	-$94.9K	–	961
2023 Q1	$94.9K	Buy	+11,402	New	+$106K	﹤0.01%	944

Other funds holding FENC

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

LMR Partners's FENC Position: Q2 2023 in Review

LMR Partners sold out of Fennec Pharmaceuticals (FENC) in Q2 2023, closing a stake of 11,402 shares — an estimated $94.9K sold.

LMR Partners first reported a position in FENC in Q1 2023 and held it in 1 quarter. The position peaked at $94.9K in Q1 2023. 56 funds tracked by Wall St. Rank hold FENC as of Q2 2023.

LMR Partners reported no remaining Fennec Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 11,402 Fennec Pharmaceuticals shares in Q2 2023, an estimated $94.9K.
LMR Partners first reported a position in Fennec Pharmaceuticals in Q1 2023 and held it in 1 quarter.
LMR Partners's Fennec Pharmaceuticals position peaked at $94.9K in Q1 2023.
56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.